Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Shield Therapeutics plc

Healthcare GB STX

6.15GBX
0.35(6.03%)

Last update at 2026-06-05T15:27:00Z

Day Range

5.756.30
LowHigh

52 Week Range

2.1012.50
LowHigh

Fundamentals

  • Previous Close 5.80
  • Market Cap95.05M
  • Volume2820116
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.37700M
  • Revenue TTM41.49M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 20.06M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -20.78239M -32.37500M -40.08200M -19.56500M -1.88600M
Minority interest - - - - -
Net income -21.27229M -33.29300M -40.44400M -19.33600M -2.63000M
Selling general administrative 10.76M 15.17M 27.33M 20.02M 5.62M
Selling and marketing expenses 23.83M 21.72M 16.01M 10.26M 0.28M
Gross profit 10.57M 4.03M 2.00M 0.54M 9.03M
Reconciled depreciation 1.43M 1.07M 2.36M 2.21M 2.71M
Ebit -17.69196M -31.35900M -25.70600M -19.95200M -1.88600M
Ebitda -16.57677M -30.28800M -22.62300M -17.35000M 0.82M
Depreciation and amortization 1.12M 1.07M 3.08M 2.60M 2.71M
Non operating income net other - - - - -
Operating income -17.97603M -31.33100M -25.70600M -19.95200M -1.88600M
Other operating expenses 43.16M 44.42M 30.17M 21.47M 12.54M
Interest expense 3.09M 0.82M 0.39M 0.00800M 0.00000M
Tax provision 0.63M 0.92M 0.36M -0.22900M 0.74M
Interest income 0.27M 0.52M 0.72M 0.40M 0.00300M
Net interest income -3.60700M -0.50100M 0.33M 0.39M 0.00200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.49M 0.92M 0.36M -0.22900M 0.74M
Total revenue 25.18M 13.09M 4.47M 1.52M 10.39M
Total operating expenses 37.80M 35.36M 27.70M 20.49M 11.19M
Cost of revenue 14.61M 9.06M 2.47M 0.98M 1.35M
Total other income expense net -2.80636M -1.04400M -14.37600M 0.39M 0.27M
Discontinued operations - - - - -
Net income from continuing ops -27.18200M -33.29300M -40.44400M -19.33600M -2.63000M
Net income applicable to common shares - - -40.44400M -19.33600M -2.63000M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 45.90M 48.80M 22.07M 44.41M 32.53M
Intangible assets 14.51M 16.86M 11.78M 26.85M 27.27M
Earning assets - - - - -
Other current assets 0.00000M 3.51M - 3.51M 0.91M
Total liab 46.95M 26.49M 16.65M 3.38M 2.25M
Total stockholder equity -1.05158M 11.79M 5.43M 41.03M 30.28M
Deferred long term liab - - - 9.53M 8.43M
Other current liab 7.18M 6.25M 1.06M 0.11M 0.75M
Common stock 15.90M 11.78M 3.89M 3.24M 1.76M
Capital stock 19.91M 15.01M 3.89M 3.24M 1.76M
Retained earnings -172.95353M -233.52500M -146.63800M -106.59500M -88.25100M
Other liab - - 0.47M - -
Good will - - - - -
Other assets - -10.51927M - 9.53M 8.43M
Cash 5.61M 13.95M 2.82M 12.12M 2.94M
Cash and equivalents - - - - -
Total current liabilities 26.05M 10.77M 10.64M 3.38M 2.25M
Current deferred revenue - 0.00000M - - -
Net debt 15.45M 6.46M 3.28M -11.96100M -2.91200M
Short term debt 0.35M 0.38M 0.09M 0.16M 0.03M
Short long term debt - - - - -
Short long term debt total 21.06M 20.41M 6.10M 0.16M 0.03M
Other stockholder equity 197.67M 233.54M 148.17M 144.39M 116.76M
Property plant equipment - - 0.20M 0.30M 0.03M
Total current assets 30.29M 31.26M 10.09M 17.26M 5.23M
Long term investments - - - - -
Net tangible assets - - -6.35600M 23.71M 11.44M
Short term investments - -3.00668M - - -
Net receivables 20.16M 10.60M 5.38M 1.77M 0.66M
Long term debt 26.17M 19.84M 6.01M - -
Inventory 4.52M 3.20M 1.46M 1.64M 1.38M
Accounts payable 18.51M 4.05M 9.49M 3.11M 1.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -6.23283M -6.63006M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 1.76M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M -3.63504M - 26.85M -
Deferred long term asset charges - - - - -
Non current assets total 15.60M 17.54M 11.98M 27.16M 27.30M
Capital lease obligations 0.20M 0.41M 0.09M 0.16M 0.03M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -2.15500M -2.43000M -1.69500M -2.05100M -0.02000M
Change to liabilities - - 6.03M 1.64M -2.07500M
Total cashflows from investing activities -1.89464M -2.43000M -1.69500M -2.05100M -0.02000M
Net borrowings 0.00000M 24.00M 8.10M -0.07600M -0.04800M
Total cash from financing activities 4.21M 49.66M 7.71M 27.58M -0.04700M
Change to operating activities - - 0.95M -0.51500M 0.15M
Net income -21.27229M -33.29300M -40.44400M -19.33600M -2.63000M
Change in cash -5.33289M 10.55M -9.29600M 9.18M -1.20100M
Begin period cash flow 10.94M 3.40M 12.12M 2.94M 4.14M
End period cash flow 5.61M 13.95M 2.82M 12.12M 2.94M
Total cash from operating activities -7.00651M -37.12600M -18.24700M -16.73800M -1.40000M
Issuance of capital stock 0.12M 26.82M 0.09M 27.70M 0.00600M
Depreciation 1.12M 1.07M 2.36M 2.21M 2.71M
Other cashflows from investing activities - -2.19100M 0.20M 0.01M 0.00300M
Dividends paid - - - - -
Change to inventory -1.92360M -1.16327M 0.18M -0.25600M -0.43100M
Change to account receivables -0.89371M -5.63693M -2.45100M -2.87900M -0.26400M
Sale purchase of stock - 0.00000M -0.08200M - -
Other cashflows from financing activities -0.16669M -1.15900M 7.70M -0.12100M -0.05300M
Change to netincome - - 15.13M 2.40M 1.15M
Capital expenditures 0.03M 2.95M 1.90M 2.06M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 12.58M -7.02400M 4.71M -2.00700M -2.62200M
Stock based compensation 0.86M 0.88M 0.74M 0.99M 0.77M
Other non cash items 0.57M 1.25M 14.38M -0.35300M -0.26800M
Free cash flow -7.03390M -40.07400M -20.14200M -18.80200M -1.42300M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
STX
Shield Therapeutics plc		 0.35 6.03% 6.15 - 65.36 2.24 76.33 3.34 -1.4946
HLN
Haleon PLC		 7.20 2.18% 337.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 11.00 0.75% 1471.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 -11.0 6.38% 161.50 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 -0.4 4.49% 8.50 - 106.38 11.72 159.47 12.12 -4.1496

Reports Covered

Stock Research & News

View All

Profile

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Shield Therapeutics plc

Northern Design Centre, Gateshead, United Kingdom, NE8 3DF

Key Executives

Name Title Year Born
Mr. Gregory P. Madison CEO & Exec. Director 1968
Dr. Christian Schweiger M.D., Ph.D. Co-Founder & Non Exec. Director 1967
Mr. Hans-Peter Rudolf Chief Financial Officer NA
Ms. Lucy Huntington-Bailey Gen. Counsel & Company Sec. NA
Ms. Suzanne Wood Group HR Director NA
Ms. Carol Akinola Head of Pharmacovigilance & Medical Information NA
Dr. José A. Menoyo M.D. Chief Medical Officer NA
Mr. Anders Lundstrom CEO & Executive Director 1962
Dr. Christian Schweiger M.D., Ph.D. Co-Founder & Non Executive Director 1966
Mr. Santosh Shanbhag Chief Financial Officer 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions